PMID- 16512994
OWN - NLM
STAT- MEDLINE
DCOM- 20060428
LR  - 20191109
IS  - 1533-0028 (Print)
IS  - 1533-0028 (Linking)
VI  - 5
IP  - 5
DP  - 2006 Jan
TI  - Clinical significance of immunohistochemical expression of hypoxia-inducible 
      factor-1alpha as a prognostic marker in rectal adenocarcinoma.
PG  - 350-3
AB  - BACKGROUND: Hypoxia-inducible factor-1alpha (HIF-1alpha), a subunit of 
      hypoxia-inducible factor-1 (HIF-1), furnishes tumor cells with the means of 
      adapting to stress parameters, such as tumor hypoxia, and promotes critical steps 
      in tumor progression and aggressiveness by inducing angiogenesis and regulating 
      energy metabolism. In this study, we investigated the relationship between 
      HIF-1alpha and vascular endothelial growth factor (VEGF) and clinicopathologic 
      characteristics, and evaluated the role of HIF-1alpha expression in patients with 
      rectal adenocarcinoma. PATIENTS AND METHODS: The immunohistochemical expression 
      of HIF-1alpha and VEGF was evaluated in 30 formalin-fixed, paraffin-embedded 
      postoperative rectal adenocarcinoma tissue samples. Correlations with 
      clinicopathologic characteristics were determined by cross-tabulations. The 
      impact of the immunoreactivity of HIF-1alpha with regard to the overall survival 
      and local control endpoints was determined by univariate analyses. RESULTS: 
      Increased HIF-1alpha expression was strongly associated with VEGF positivity (P = 
      0.002), Dukes stage (P = 0.017), and lymph node metastasis (P = 0.001). No 
      correlation was found between the level of HIF-1alpha expression and histologic 
      grade (P = 0.63). The Kaplan-Meier curves showed a significantly shorter overall 
      survival (P = 0.0087) and local control (P = 0.0438) for patients with high 
      HIF-1alpha expression. CONCLUSION: These results show that HIF-1alpha might 
      represent an important biologic marker evaluating the prognosis of patients with 
      rectal adenocarcinoma.
FAU - Lu, Xue-guan
AU  - Lu XG
AD  - Second Hospital Affiliated of Suzhou University, Suzhou, China. 
      luxueguanok@yahoo.com.cn
FAU - Xing, Chun-gen
AU  - Xing CG
FAU - Feng, Yi-zhong
AU  - Feng YZ
FAU - Chen, Jie
AU  - Chen J
FAU - Deng, Chong
AU  - Deng C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Colorectal Cancer
JT  - Clinical colorectal cancer
JID - 101120693
RN  - 0 (Biomarkers)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adenocarcinoma/*metabolism/*mortality/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Rectal Neoplasms/*metabolism/*mortality/pathology
MH  - Survival Rate
MH  - Vascular Endothelial Growth Factor A/metabolism
EDAT- 2006/03/04 09:00
MHDA- 2006/04/29 09:00
CRDT- 2006/03/04 09:00
PHST- 2006/03/04 09:00 [pubmed]
PHST- 2006/04/29 09:00 [medline]
PHST- 2006/03/04 09:00 [entrez]
AID - S1533-0028(11)70207-9 [pii]
AID - 10.3816/ccc.2006.n.005 [doi]
PST - ppublish
SO  - Clin Colorectal Cancer. 2006 Jan;5(5):350-3. doi: 10.3816/ccc.2006.n.005.